EP2805720A1 — Non-hormonal steroid modulators of NF-KB for treatment of disease

USPTO Abstract

The present invention is directed to a compound for use in reducing the symptoms of muscular dystrophy, wherein said compound has structural Formula I: wherein: said dashed line indicates an optional double bond; each R 1 is hydrogen; R 2 is selected from the group consisting of hydrogen and methyl; R 3 is selected from the group consisting of hydrogen, hydroxyl, and methyl; or R 2 and R 3 may be taken together to form a double bond; R 4 is -(CO) n (C(R 5 )(R 6 )) m (R 7 ); R 5 and R 6 are independently selected from the groups consisting of hydrogen and C 1-3 alkyl; R 7 is selected from the group consisting of -N(R 8 )(R 9 ) and -OR 10 ; R 8 , and R 9 are each independently selected from the group consisting of hydrogen, lower alkyl, and -(C(R 5 ) 2 ) p R 11 ; or R 8 and R 9 may be taken together to form a heterocycloalkyl; R 10 is selected from the group consisting of hydrogen, acyl, lower alkyl, and-(C(R 5 ) 2 ) p R 11 ; R 11 is selected from the group consisting of hydroxyl and amino; n is 0 or 1; m is an integer between 1 and 3; p is an integer between 1 and 3; and q is an integer between 1 and 4.